期刊文献+

紫草素对卵巢癌细胞SKOV3/DDP顺铂耐药的逆转作用 被引量:11

Reversal effect of shikonin on cisplatin resistance of ovarian cancer SKOV3/DDP cells
下载PDF
导出
摘要 目的:探讨紫草素是否逆转卵巢癌细胞SKOV3/DDP的顺铂耐药效应及其作用机制。方法:采用CCK-8法确定紫草素和顺铂的最佳作用条件,流式细胞术检测细胞的周期分布及凋亡率;Western blot检测周期及凋亡相关调控因子细胞周期蛋白D1(cyclin D1)、周期蛋白依赖性激酶2(CDK2)、P18、p-Rb、Bcl-2、Bax和cleaved caspase-3的蛋白水平。结果:CCK-8实验结果显示,相较于单用顺铂,联合使用紫草素对顺铂耐药卵巢癌细胞SKOV3/DDP的生长抑制作用较为显著。此外,联用紫草素和顺铂可显著抑制细胞周期G_1/S转化,并增加细胞早期凋亡率。Western blot结果显示,相较于顺铂处理组,紫草素和顺铂联用组的cyclin D1、CDK2、p-Rb及Bcl-2的蛋白水平显著降低,而P18、Bax及cleaved caspase-3的蛋白表达显著增加。结论:紫草素可逆转卵巢癌SKOV3/DDP细胞的顺铂耐药效应,其作用机制可能与影响细胞周期及凋亡相关因子的表达,进而抑制细胞活力促进细胞凋亡相关。 AIM:To explore the reversal effect of shikonin on cisplatin resistance of ovarian cancer SKOV3/DDP cells and its potential mechanism.METHODS:The proper conditions of treatment with shikonin and cisplatin were determined by CCK-8 assay.The cell cycle and apoptotic rate were analyzed by flow cytometry.The protein levels of cell cycle-and apoptotic-related molecules,such as cyclin D1,cyclin-dependent kinases 2(CDK2),P18,p-Rb,Bcl-2,Bax and cleaved caspase-3,were determined by Western blot.RESULTS:The results of CCK-8 assay showed that compared with cisplatin group,combined treatment with shikonin and cisplatin had a better inhibitory effect on the growth of cisplatin-resistant SKOV3/DDP cells.The cell cycle G 1/S transition was inhibited,while early apoptotic rate was increased after combined use of shikonin and cisplatin.The results of Western blot showed that compared with cisplatin group,the cells in combination group had lower protein levels of cyclin D1,CDK2,p-Rb and Bcl-2,accompanied with higher protein levels of P18,Bax and cleaved caspase-3.CONCLUSION:Shikonin reverses the cisplatin resistance of ovarian cancer SKOV3/DDP cells.The mechanism may be related to the regulation of cell cycle-and apoptotic-related molecules,and further inhibition of cell viability and promotion of cell apoptosis.
作者 许静 郭哲 王秋宇 梁殿迅 XU Jing;GUO Zhe;WANG Qiu-yu;LIANG Dian-xun(Department of Obstetrics and Gynecology,Nanyang Center Hospital,Nanyang 473000,China)
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2018年第9期1616-1621,共6页 Chinese Journal of Pathophysiology
关键词 紫草素 卵巢癌 顺铂 细胞凋亡 细胞周期 Shikonin Ovarian cancer Cisplatin Apoptosis Cell cycle
  • 相关文献

参考文献2

二级参考文献27

  • 1王晓红,符立梧.凋亡抑制蛋白家族与肿瘤治疗的研究进展[J].药学学报,2006,41(2):103-107. 被引量:5
  • 2任新玲,钱桂生,金伯泉,沈丽英.Egf/r3单克隆抗体治疗肺腺癌的实验研究[J].临床肿瘤学杂志,2006,11(4):262-266. 被引量:1
  • 3黄胜辉,黄志勇.PARP一1:一个肿瘤治疗的新靶点[J].世界华人消化杂志,2006,14(9):841-847.
  • 4Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29.
  • 5Johnson JL, Pillai S, Chellappan SP. Genetic and biochemical alterations in non-small cell lung cancer [J]. Biochemistry research international, 2012, 2012" 940405.
  • 6Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) [J]. Journal of clinical ontology: official journal of the American Society of Clinical Oncology, 2011, 29(21): 2866-2874.
  • 7Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2010, 28(2): 357-360.
  • 8Li W, Ren S, Li J, et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients[J]. Lung Cancer, 2014, 84(3): 295-300.
  • 9Rolfo C, Giovannetti E, Hong DS, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors[J]. Cancer Treat Rev, 2014, 40(8): 990-1004.
  • 10Gong K, Zhang Z, Chen Y, et al. Extracellular sigual-regulated kinase, receptor interacting protein, and reactive oxygen species regulate shikonin-induced autophagy in human hepatocellular carcinoma [J]. European journal of pharmacology, 2014, 738:142-152.

共引文献53

同被引文献131

引证文献11

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部